Abdulrahman Ayfan

Abdulrahman Ayfan

Auto-generated profile, based on publicly available information

Abdulrahman Ayfan

Faculty of Science, Biochemistry Department, King Abdul-Aziz University (KAU), Jeddah, Kingdom of Saudi Arabia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
AAAbdulrahman K. S. Ayfan
Abdulrahman K. S. Ayfan
JMJoanne Macdonald
Joanne Macdonald
PHPatrick Harris
Patrick Harris
CHClaire Heney
Claire Heney
DPDavid Paterson
David Paterson
AIAdam Irwin
Adam Irwin

1 October 2020 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
SLS. Mohd Sazlly Lim
S. Mohd Sazlly Lim
SNS. Naicker
S. Naicker
AAA.K. Ayfan
A.K. Ayfan
HZH. Zowawi
H. Zowawi
JRJ.A. Roberts
J.A. Roberts
FSFekade Sime
Fekade Sime

1 February 2020 in Journal of Infection and Public Health
Verified
Journal Article
Open access
AAA Ayfan
A Ayfan
NEN Ertl
N Ertl
DWD Whiley
D Whiley
DPD Paterson
D Paterson
CHC Heney
C Heney
HZH Zowawi
H Zowawi

8 January 2019 in Journal of Infection and Public Health
Verified
Journal Article
Open access
PDF file
AAA. Ayfan
A. Ayfan
SRS. Reed
S. Reed
DPD. Paterson
D. Paterson
HZH. Zowawi
H. Zowawi

19 May 2025
Verified
Thesis
Closed access
AAAbdulrahman Ayfan
Abdulrahman Ayfan
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.

14 August 2026 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
AAAbdulrahman K. S. Ayfan
Abdulrahman K. S. Ayfan
DWDavid David Whiley
David David Whiley
LRLeah W. Roberts
Leah W. Roberts
Purpose: Mutations in the Neisseria gonorrhoeae (NG) gyrA codons 91 and 95 are known to confer resistance to ciprofloxacin, but questions remain over whether all the various permutations of these codons are needed for optimal molecular detection of NG ciprofloxacin susceptibility. Here, we used publicly available sequence data to answer this question to help inform the design of next-generation NG gyrA assays. Methods: NG gyrA alleles ( n = 73) were downloaded from the NG-STAR platform, as were all NG sequences and associated metadata from Pathogenwatch ( n = 38,367 records; n= 31,114 following de-duplication). Analyses focused on understanding the frequency of NG gyrA 91 and 95 alterations and the applicability of assay designs to detect ciprofloxacin resistance. Results: While the 73 NG-STAR alleles reflect considerable gyrA sequence diversity, just four amino acid combinations at codons 91 and 95 (wild-type; S91F/D95A; S91F/D95G; S91F/D95N) comprised > 99% of isolates. Also, 91-only and 95-only mutants are rare, comprising less than 1% of sequences, and moreover were typically sporadic temporally and genetically (e.g., within and across different MLSTs). The results also indicate that certain NG-STAR alleles (e.g., gyrA_42.0 , gyrA_53.0 , and gyrA_60.0 ) have high sequence homology with other commensals, including Neisseria meningitidis , and hence warrant careful consideration during assay design to avoid off-target detection. Conclusion: The results highlight that 91-only and 95-only mutants do occur at relatively low frequency, and hence assays should ideally detect both SNPs independently , with 91 as the priority. However, an assay targeting either codon alone, or both codons collectively without independently discriminating each codon, would still correctly classify approximately 99% of resistant alleles. The 0.47% of single-codon mutants, if not accounted for by an assay, nonetheless carry a real, if small, risk of false-susceptible results at the individual patient level. Local validation against contemporary sequence diversity, ideally integrated with the European Centre for Disease Prevention and Control (ECDC) Euro-GASP framework, remains essential for any assay design and deployment decision.